Vaxart, Inc., a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its vector-adjuvant-antigen standardized technology proprietary oral vaccine platform in the United States. The company's product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions. It has a license agreement with Altesa Biosciences, Inc. to develop and commercialize Vapendavir, a capsid-binding broad-spectrum antiviral. Vaxart, Inc. is headquartered in South San Francisco, California. Show more
170 Harbor Way, South San Francisco, CA, 94080, United States
Start AI Chat
Market Cap
153.6M
52 Wk Range
$0.26 - $0.84
Previous Close
$0.59
Open
$0.58
Volume
212,247
Day Range
$0.57 - $0.64
Enterprise Value
74.52M
Cash
28.79M
Avg Qtr Burn
N/A
Insider Ownership
0.93%
Institutional Own.
0.05%
Qtr Updated
09/30/25
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
| Drug & Indication | Stage & Event | Catalyst Date |
|---|---|---|
VXA-CoV2-1 oral pill Details COVID-19 | Phase 2b Data readout | |
Monovalent Norovirus Vaccine Details Norovirus | Phase 2b Update | |
Oral Bivalent Norovirus Vaccine Details Norovirus | Phase 2 Update | |
VXA-A1.1 Details Influenza | Phase 2 Update | |
Phase 1 Data readout | ||
Oral Bivalent Norovirus Vaccine Details Norovirus | Phase 1 Update |
